Background: Accumulating evidence suggests that regulatory B cells (Bregs) play an important role in modulating the immune response to tumours. Our previous study indicated that a small percentage of peripheral CD19 + CD24 h CD27 + Breg cells slowed gastric cancer progression in XELOX-treated patients. Here, we further investigated the relationship between dynamic changes in circulating Breg cells and the clinical course in XELOX-treated gastric cancer patients. Methods: A total of 52 patients with advanced gastric cancer were enrolled in this study. The frequencies of CD19 + CD24 h CD27 + cells in peripheral blood were tested before (as a baseline) and 9 weeks after administration of oxaliplatin and capecitabine (XELOX). The primary endpoint of the study was progression-free survival time (PFS) of the patients. The overall survival (OS) and adverse events of chemotherapy were also recorded. Results: The median PFS of patients was 6 months (95% CI, 5.27-6.73) with effective rate of 46.2%. The percentage of CD19 + CD24 h CD27 + cells in lymphocytes ranged from 0.007% to 1.94%, with a median value of 0.45%. The median percentage of CD19 + CD24 h CD27 + lymphocytes was 0.59% (0.01%-6.02%) 9 weeks after treatment. There were no significant differences for this index. However, the patients with decreased Breg frequencies after XELOX treatment had a longer PFS time (7.0 months vs. 5.0 months, p=0.01) than those with increased Breg frequencies.
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Conclusion: Patients with downtrend of CD19
+ CD24 h CD27 + B lymphocytes during early stages of chemotherapy relative to their initial values had longer PFS times, and this could be used to predict the efficacy of chemotherapy and help physicians adjust treatments accordingly.
Introduction
Gastric cancer is the third leading cause of cancer-related deaths worldwide, with a high incidence and mortality rate in East Asia [1] . In most cases, the disease is asymptomatic during early stages and diagnosed at advanced stages. Chemotherapy and radiation as palliative treatments are adopted for advanced disease [2] .
A combination of fluoropyrimidine and platinum agents, such as the XELOX regimen, has been proven efficacious and safe as a first-line treatment for gastric cancers [3, 4] . However, more than one third of gastric cancer patients gain no benefit after they have received the XELOX regimen, and the underlying reason remains unknown. The immune status in humans may be linked with cancer resistance to chemotherapy in several cancers [5, 6] . Our previous study demonstrated that a reduction in peripheral Breg cells in gastric cancer patients treated with XELOX was associated with a slower cancer progression [7] .
"Regulatory B cells" were introduced by Mizoguchi and colleagues, who identified Bregs as an IL-10-producing B cell subset in 2002 [8] . Until recently, the exact surface molecules of Bregs have been elusive. Various markers, alone or combined with others, were used to identify Bregs in different situations. In human, Bregs were enriched in both transitional (CD24 
CD27
+ Bregs is to regulate inflammation. Some studies have indicated that the tumour inhibition effect of T cells was regulated by IL-10, which made the point that Bregs might be involved in cancer immunity [11] . The mechanism of Bregs in human cancer has not been fully understood until now. In this study, we explore changes in Breg levels from the peripheral blood of patients with advanced gastric cancer receiving XELOX chemotherapy.
Methods and Patients
Patients
Patients diagnosed with stage IV gastric cancer were eligible for participation in this study. Enrolled patients 18 years of age or older were defined by an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0, 1, or 2 (on a scale from 0 to 5, a score of 0 indicates no symptoms, 1 mild symptoms, 2 symptomatic, <50% in bed during the day). Patients with autoimmune disease, systemic immunosuppression, or prior antitumour therapy were excluded from this study. HER2 positive patients were eligible for the study but not patients who had received anti-HER2 therapy.
Study design
This is a single centre exploratory study. The protocol was approved by the ethics committee of Zhongshan Hospital, Fudan University (ethical approval No. B2015-049) and was in compliance with the Helsinki Declaration. All patients provided written informed consent before any study-related procedures.
Peripheral blood samples were collected before (as a baseline) and after the third cycle of XELOX (intravenous oxaliplatin 130 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 twice daily, from day 1 to 14 in 21-day cycles). Efficacy was assessed by CT scan every three cycles of the XELOX regimen. Patients discontinued treatment until occurrence of complete response, serious adverse events, disease progression, or the patient's request for withdrawal. In cases where the XELOX regimen ceased, further treatments would be provided after discussion with the patient.
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from the blood samples of 52 patients collected before and after three cycles of XELOX chemotherapy. Purified PBMCs were rinsed twice with phosphate-buffered saline (PBS), suspended at a concentration of 1 × 10 6 cells/ml and stained with the following fluorescein-labelled antibodies (Ab): CD19-FITC, CD24-Percp-cy5.5 and CD27-PE (BD Pharmingen). Thereafter, cells were washed twice with 2 ml 1× permeabilization buffer and resuspended in flow cytometry staining buffer (eBioscience). Samples were detected by flow cytometry on an FACS Aria BD II flow cytometer, which was followed by analysis with FlowJo 10.1 software (Tree Star, San Carlos, CA). Cells stained with isotype control antibody served as the negative control. Compensation was made according to single staining.
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Measurement index
The main measurement index was the percentage of CD19
+ lymphocyte subsets before and 9 weeks after chemotherapy. Other indexes were also recorded, including the efficacy of the XELOX regimen as a first-line chemotherapy, progression-free survival, and adverse effects.
Clinical and laboratory tests were performed to assess safety on patients before and after 9 weeks of chemotherapy. Efficacy evaluation was based on the Response Evaluation Criteria in Solid Tumours RECIST Version 1.1 (RECIST) [12] . The degree of adverse events was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 [13] .
Lymphocyte subsets were analysed using FACS at the cell laboratory in our hospital. Five millilitres of fasting peripheral blood from patients were collected into EDTA anticoagulant tubes before and 9 weeks after chemotherapy and analysed within 4 hours. Data were presented as the percentage of CD19 + cells within lymphocytes or the percentage of CD19
+ cells within lymphocytes.
Statistical analysis
Progression free survival was stratified and analysed using a bilateral rank-log test. Stratification was based on the changes of Breg cells before and after chemotherapy. A 95% confidence interval (CI) was calculated using the Clopper-Pearson method. All patients received at least one cycle of chemotherapy with the XELOX regimen, and the median cycle number was 6 (between 1 and 16). By the last follow-up, a total of 48 patients experienced disease progression (92.3%), of which 21 patients died. There were 4 patients with no disease progression, one of them had tumour regression after 3 cycles of chemotherapy. This one patient accepted radical surgery after multidisciplinary discussion. The other 3 patients were administered more than 6 months (8 cycles) of XELOX followed by maintenance treatment using only capecitabine.
Breg levels
The levels of CD19 + and Breg cells were measured in all 52 patients before treatment ( Fig. 1) and in 51 patients 9 weeks after chemotherapy. The results show that the median baseline level of CD19 + cells in lymphocytes was 5.05% (0.79% -21.2%), and the median level of CD19
+ lymphocyte subsets was 0.45% (0.007% -1.94%). After 3 cycles of XELOX treatment (1 patient received only 1 cycle because of disease progression, who survived for 1 month after treatment), the median level of CD19 + cells was 6% (1.2% to 16.5%). The median percentage of CD19
+ lymphocyte subsets was 0.59% (0.01% -6.02%) (Fig. 2) . Compared to the levels before chemotherapy, there were no significant differences for either index.
The efficacy and adverse events of chemotherapy
The XELOX regimen is the classic clinical chemotherapy for gastric cancer. In this study, the effective rate was 46.2% (25/52) with 25 partial responses (PR). Median progression free survival time was 6 months (95% CI, 5.27-6.73) (Fig. 3) , which was consistent with previous reports [3, 14] .
The main adverse events during XELOX treatment were bone marrow suppression, nausea, vomit, and hand foot syndrome. Grade 3 or 4 adverse reactions occurred in 51.9% of patients (27/52). However, those patients could continue XELOX therapy after supportive treatment or dose reduction. 
CD27
+ lymphocyte subsets within patients, no relation was found between patients' responses and progression free survival (data not shown) to chemotherapy.
We then grouped patients according to changing trends in CD19
lymphocytes after chemotherapy and compared disease-free survival in patients with upward trends versus patients with downward trends. The latter median PFS was significantly longer than that of the former (7 months vs 5 months, p=0.0042, Fig. 4A ). In addition, we grouped patients based on changing Breg/B ratios after chemotherapy; the median PFS of patients with a decreased ratio was also significantly longer than those with an increased ratio (7 months vs 5 months, p=0.0089, Fig. 4B ).
Discussion
We failed to find a correlation between baseline Breg levels and a response to chemotherapy in advanced gastric cancer patients. However, we observed that patients with a reduction in peripheral CD19
+ cell frequency 9 weeks after XELOX treatment had a longer PFS time than those with an increase in Breg frequency. A change in Breg frequency can act as a predictive index for the efficacy of XELOX treatment, which could have a significant role in the clinical management of gastric cancers.
Immune status has been correlated with prognosis in several cancer types [15, 16] . In gastric cancer patients, intratumoural infiltrations of cytotoxic T cells and memory cells were shown to indicate better prognoses and survival outcomes [17] , while patients with higher tumour-associated microphage (TAM) infiltration had worse surgical outcomes [18, 19] . Maskey et al. assessed the immune response in gastric cancer patients after neoadjuvant chemotherapy (NACT) and found that those with a low expression of B7-H4 in their tumours had significantly longer OS [20] . Furthermore, the density of mast cell-derived IL-17 had significant positive correlations with microvessels, neutrophils, and regulatory T cells (Tregs). Therefore, increasing intratumour infiltrated IL-17 + mast cells was significantly associated with worse OS outcomes [21] . However, these indicators in tumour tissues would require invasive biopsies, and the results would be significantly affected by the location of the specimen. Here, we demonstrate, for the first time, the predictive role of peripheral Breg frequency in gastric cancer patients during chemotherapy. Patients with a reduction in Breg cells in their PBMCs 9 weeks after chemotherapy had longer PFS than those with an increase in Breg cells. This idea was supported by another study, in which the authors showed that decreased ratios of peripheral Breg cells were associated with a better prognosis in liver cancer patients treated with sorafenib [22] . Importantly, we did not detect any correlation between baseline Breg frequency and chemotherapeutic benefit, suggesting that Breg levels vary greatly among individuals. In addition, our previous work failed to detect any significant difference in Breg frequencies among PBMCs from patients with advanced gastric cancers and corresponding healthy adults (unpublished data). Thus, the dynamic changes in peripheral Breg cells was more important in predicting chemotherapeutic benefit in gastric cancers during early stages of treatment. Notably, the trend in Breg frequency presented 9 weeks after chemotherapy, which was much earlier than the manifestation of imaging followups (such as CT scans). Therefore, changes in Breg cells during early stages of chemotherapy can help physicians adjust treatment strategies for patients if necessary.
A large body of evidence demonstrates that the antitumour effect of some chemotherapy drugs is mediated, at least in part, by inducing immunogenic cell death (ICD), which is commonly used to indicate a peculiar instance of regulated cell death that engages the adaptive immune system [23] . Immunogenic apoptosis of cancer cells can induce an effective antitumour immune response through activation of dendritic cells (DCs) and a consequent specific T cell response. Oxaliplatin, a platinum derivative approved for use in combination with capecitabine to treat gastric and advanced colorectal cancers, has been reported to induce immunogenic death in colon cancer cells in vitro and in mouse models [24, 25] . Clearly, as part of its intended therapeutic effect, XELOX therapy induces tumour cell death in our patients. Cell death results in a release of tumour antigens and emission of dangerassociated molecular patterns in the tumour microenvironment. This favourable immune microenvironment is partially reflected by a reduction in circulating Breg cells, which have been reported to play a suppressive role in the immune response against tumours [26, 27] . Furthermore, our previous study found that B cells, especially CD19
+ B cells, were more sensitive to capecitabine-oxaliplatin stimulation than other immune cells in vitro [7] . This indicates that chemotherapy drugs might directly promote cancer immunity by releasing suppressive effects other than ICD. However, approximately 60% of the patients had increased Breg frequency after chemotherapy, predicting a poor prognosis. It will be interesting to see if these patients can benefit from a combination of chemotherapy and immunotherapy by blocking immunosuppressive receptors. Harnessing the immune system to fight tumours is becoming an attractive and effective therapy option that leads to dramatic and durable responses in several cancer types. The administration of immune checkpoint blockers has been shown to improve the clinical profile of various chemotherapeutic agents [28] . In addition, various combinatorial immuno-and chemo-therapeutic regimens are being investigated in animal models and clinical trials to assess their antineoplastic efficacies [23, 29] . On the other hand, targeting the cancer microenvironment to relieve suppressive factors might benefit chemotherapeutic efficacy. It has been reported that resveratrol inhibits breast cancer metastasis in mice by inactivating tumour-evoked Breg cells [30] . Resveratrol inactivates Stat3 and prevents the generation and function of tumour-evoked Bregs (tBreg). It releases antitumour effector immune responses by disabling tBreg-induced conversions of Foxp3+ Tregs. Thus, it is worthwhile to investigate whether immunomodulatory drugs, such as resveratrol, can boost chemotherapeutic effects.
In summary, we observed that the XELOX regimen altered the population of CD19
+ lymphocyte subsets in peripheral blood as early as 9 weeks after treatment, indicating that the chemotherapeutic agents modulated the anticancer immune response. Importantly, the change in CD19 
